TipRanks

Notifications

Tag: MRNA

Total 525 Posts

Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Moderna (MRNAResearch Report), Altimmune (ALTResearch Report) and Bausch Health Companies (BHCResearch Report) with bullish sentiments.

Moderna (MRNA)

Jefferies analyst Michael Yee maintained a Buy rating on Moderna today and set a price target of $125.00. The company’s shares closed last Wednesday at $110.59.

According to TipRanks.com, Yee is a 3-star analyst with an average return of 0.7% and a 44.0% success rate. Yee covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Vertex Pharmaceuticals, and Olema Pharmaceuticals.

Currently, the analyst consensus on Moderna is a Moderate Buy with an average price target of $134.69, implying a 22.9% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $206.00 price target.

See the top stocks recommended by analysts >>

Altimmune (ALT)

Jefferies analyst Roger Song maintained a Buy rating on Altimmune today and set a price target of $35.00. The company’s shares closed last Wednesday at $8.89.

According to TipRanks.com, Song has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.7% and a 33.9% success rate. Song covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics, Nektar Therapeutics, and Viking Therapeutics.

Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $24.00, implying a 157.5% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $25.00 price target.

Bausch Health Companies (BHC)

Jefferies analyst Glen Santangelo maintained a Buy rating on Bausch Health Companies today and set a price target of $16.00. The company’s shares closed last Wednesday at $10.49, equals to its 52-week high of $10.49.

According to TipRanks.com, Santangelo is a 4-star analyst with an average return of 7.9% and a 55.4% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Bausch Health Companies with a $10.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRNA:

Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Akebia Therapeutics (AKBA) and Moderna (MRNA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Integer Holdings (ITGRResearch Report), Akebia Therapeutics (AKBAResearch Report) and Moderna (MRNAResearch Report) with bullish sentiments.

Integer Holdings (ITGR)

In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Integer Holdings, with a price target of $130.00. The company’s shares closed last Wednesday at $115.06, close to its 52-week high of $118.15.

According to TipRanks.com, Wasserman is a 1-star analyst with an average return of -3.7% and a 34.3% success rate. Wasserman covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, AbCellera Biologics, and Ligand Pharma.

Currently, the analyst consensus on Integer Holdings is a Strong Buy with an average price target of $121.00, a 7.5% upside from current levels. In a report issued on March 14, C.L. King also initiated coverage with a Buy rating on the stock with a $137.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Akebia Therapeutics (AKBA)

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Akebia Therapeutics, with a price target of $4.00. The company’s shares closed last Wednesday at $2.24, close to its 52-week high of $2.34.

According to TipRanks.com, Bratzel is a 4-star analyst with an average return of 11.0% and a 63.4% success rate. Bratzel covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Travere Therapeutics, and Scholar Rock Holding.

Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.33, implying an 110.2% upside from current levels. In a report issued on March 15, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.

Moderna (MRNA)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Moderna, with a price target of $214.00. The company’s shares closed last Wednesday at $110.59.

According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of 5.6% and a 39.6% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Milestone Pharmaceuticals, and Arvinas Holding Company.

Moderna has an analyst consensus of Moderate Buy, with a price target consensus of $129.27, implying a 18.0% upside from current levels. In a report released yesterday, UBS also reiterated a Buy rating on the stock with a $143.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ITGR: